Mottaghy F - Search Results

1

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.

Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A. Kratochwil C, et al. Among authors: mottaghy f. J Nucl Med. 2016 Dec;57(12):1941-1944. doi: 10.2967/jnumed.116.178673. Epub 2016 Jul 7. J Nucl Med. 2016. PMID: 27390158 Free article.

2

Clinical relevance of imaging proliferative activity in lung nodules.

Buck AK, Hetzel M, Schirrmeister H, Halter G, Möller P, Kratochwil C, Wahl A, Glatting G, Mottaghy FM, Mattfeldt T, Neumaier B, Reske SN. Buck AK, et al. Eur J Nucl Med Mol Imaging. 2005 May;32(5):525-33. doi: 10.1007/s00259-004-1706-7. Epub 2004 Dec 14. Eur J Nucl Med Mol Imaging. 2005. PMID: 15599526 Clinical Trial.

3

First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine.

Buck AK, Bommer M, Juweid ME, Glatting G, Stilgenbauer S, Mottaghy FM, Schulz M, Kull T, Bunjes D, Möller P, Döhner H, Reske SN. Buck AK, et al. J Nucl Med. 2008 Nov;49(11):1756-62. doi: 10.2967/jnumed.108.055335. Epub 2008 Oct 16. J Nucl Med. 2008. PMID: 18927328 Free article. Clinical Trial.

4

Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma.

Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy FM. Luster M, et al. Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):484-93. doi: 10.1007/s00259-009-1294-7. Epub 2009 Oct 28. Eur J Nucl Med Mol Imaging. 2010. PMID: 19862519

5

Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.

Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy FM. Luster M, et al. Thyroid. 2010 May;20(5):527-33. doi: 10.1089/thy.2009.0342. Thyroid. 2010. PMID: 20450432

6

Response assessment of hormonal therapy in prostate cancer by [11C] choline PET/CT.

De Waele A, Van Binnebeek S, Mottaghy FM. De Waele A, et al. Clin Nucl Med. 2010 Sep;35(9):701-3. doi: 10.1097/RLU.0b013e3181e9faf5. Clin Nucl Med. 2010. PMID: 20706046

7

Can evaluation of targeted therapy in oncology be improved by means of 18F-FLT?

De Saint-Hubert M, Brepoels L, Mottaghy FM. De Saint-Hubert M, et al. J Nucl Med. 2010 Oct;51(10):1499-500. doi: 10.2967/jnumed.110.079020. Epub 2010 Sep 16. J Nucl Med. 2010. PMID: 20847167 Free article. No abstract available.

8

Molecular nuclear therapies for thyroid carcinoma.

Verburg FA, Brans B, Mottaghy FM. Verburg FA, et al. Methods. 2011 Nov;55(3):230-7. doi: 10.1016/j.ymeth.2011.06.002. Epub 2011 Jun 16. Methods. 2011. PMID: 21704168 Review.

9

PET and PET/CT in radiation treatment planning for prostate cancer.

Pinkawa M, Eble MJ, Mottaghy FM. Pinkawa M, et al. Expert Rev Anticancer Ther. 2011 Jul;11(7):1033-9. doi: 10.1586/era.11.51. Expert Rev Anticancer Ther. 2011. PMID: 21806327 Review.

10

Post-radiosynovectomy 90Y-PET imaging.

Prechtel HW, Verburg FA, Dautzenberg KJ, Mottaghy FM, Behrendt FF, Krohn T. Prechtel HW, et al. Among authors: mottaghy fm. Nuklearmedizin. 2011;50(4):N39. Nuklearmedizin. 2011. PMID: 21833441 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

459 results

Search Page